Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 24, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/ijms24010813
Keywords
gastric cancer; molecular subtypes; PD-L1; immunotherapy; EBV; HER2; dMMR
Ask authors/readers for more resources
Recent advances in molecular subtyping of gastric cancer have identified new clinically relevant biomarkers and potential therapeutic targets. Checkpoint inhibitors have also expanded treatment options, showing promising results in certain subgroups of gastric cancer patients. However, cytotoxic chemotherapy remains the only choice for patients who do not have these biomarkers. This study aims to investigate the prevalence, clinicopathologic features, and treatment outcomes of molecular subtypes in a new-diagnosed cohort of Western gastric cancer patients.
In recent years, the molecular subtyping of gastric cancer has led to the identification of novel clinically relevant biomarkers as well as promising therapeutic targets. In parallel, the advent of checkpoint inhibitors has expanded treatment options beyond conventional chemotherapy. Compelling evidence has shown unprecedented efficacy results for anti-PD1-based therapies in the molecular subgroups of dMMR/MSI-h, EBV+ and PD-L1 CPS+ patients, to the point that these are granted approval for gastric cancer adenocarcinoma (AGC) in several countries. Despite this, cytotoxic chemotherapy remains the only treatment choice for the considerable proportion of biomarkers-negative patients. In this context, little is known about the association between subtypes-defining biomarkers (HER2, MMR/MSI, PD-L1, and EBV) and the efficacy of standard chemotherapy in non-Asian AGC. Here, we aimed to investigate the prevalence, the clinic-pathologic features, and the impact on treatment outcome of clinical molecular subtypes in a new-diagnosed Western cohort of AGC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available